PHARMING GROUP NV PHAR
SPON ADS · ADR · CUSIP 71716E105
- SectorHealth care
- IndustryPharmaceutical Preparations
- FilingsSEC EDGAR
3
institutional holders
-1 vs Q1 2023
25.0k
shares reported held*
$290.8kreported value*
0 new
0 added
0 reduced
1 sold out
net sold ≈ $10.3k (-881 shares)
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $11.65.
Trends to Q2 2023
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q3 2022 | 4 |
| Q4 2022 | 4 |
| Q1 2023 | 4 |
| Q2 2023 | 3 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Bought or addedCut or sold out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q4 2022 | 1 | 2 |
| Q1 2023 | 1 | 2 |
| Q2 2023 | 0 | 1 |
Biggest buyers
| None |
Biggest sellers
| UBS Group AG | Sold out | -881 |
Insider purchases and sales in Q2 2023
Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.
None reported in Q2 2023.
Holders, Q2 2023
| Manager | Shares | Change |
|---|---|---|
| Cowen Prime Advisors LLC 0.09% of their portfolio | 22.5k $261.7k | Unchanged |
| MORGAN STANLEY 0.00% of their portfolio | 2.5k $29.1k | Unchanged |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. 0.00% of their portfolio | 0 $0 | Unchanged |